Advertisement
Table 1 Patient Demographics and Baseline Characteristics
| Characteristics | (N = 50) |
|---|---|
| Age, median (range), years | 50.0 (21–71) |
| < 65 years, n (%) | 46 (92.0) |
| ≥ 65 years, n (%) | 4 (8.0) |
| Sex, n (%) | |
| Male | 24 (48.0) |
| Female | 26 (52.0) |
| Geographic region, n (%) | |
| USA | 27 (54.0) |
| Europe | 22 (44.0) |
| Asia | 1 (2.0) |
| ECOG PS, n (%) | |
| 0 | 19 (38.0) |
| 1 | 31 (62.0) |
| Median time since first diagnosis (range), years | 1.6 (0.2–15.1) |
| Median time since last disease progression (range), months | 0.92 (0.33–8.61) |
| Number of prior lines of systemic anticancer therapy, n (%) | |
| 1 | 13 (26.0) |
| 2 | 18 (36.0) |
| 3 | 10 (20.0) |
| ≥ 4 | 9 (18.0) |
| Receiving concomitant mitotane, n (%) | 25 (50.0) |
| PD-L1 expression on tumor cells (≥1% cutoff), n (%) | |
| Negative | 27 (54.0) |
| Positive | 15 (30.0) |
| Not evaluable | 8 (16.0) |
| PD-L1 expression on tumor cells (≥5% cutoff), n (%) | |
| Negative | 30 (60.0) |
| Positive | 12 (24.0) |
| Not evaluable | 8 (16.0) |
